CRTH.F Stock Overview
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CARsgen Therapeutics Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.67 |
| 52 Week High | HK$1.67 |
| 52 Week Low | HK$1.67 |
| Beta | 0.31 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -18.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| CRTH.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 3.2% | 1.7% |
| 1Y | n/a | 6.2% | 26.3% |
Return vs Industry: Insufficient data to determine how CRTH.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CRTH.F performed against the US Market.
Price Volatility
| CRTH.F volatility | |
|---|---|
| CRTH.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CRTH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CRTH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 525 | Zonghai Li | www.carsgen.com |
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies in China and the U.S. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and Phase I for pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; and CT011, which is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, which targets CD19 that is in Phase I/II clinical trial for the treatment of B cell non-Hodgkin’s lymphoma; CT0180, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma; and CT0181, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive hepatocellular carcinoma.
CARsgen Therapeutics Holdings Limited Fundamentals Summary
| CRTH.F fundamental statistics | |
|---|---|
| Market cap | US$486.75m |
| Earnings (TTM) | -US$127.88m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.8x
P/E RatioIs CRTH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRTH.F income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥920.38m |
| Earnings | -CN¥920.38m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.2% |
How did CRTH.F perform over the long term?
See historical performance and comparison